Studies two blood proteins during acute heart failure
Checks whether two blood proteins rise during acute heart failure in adults.
Plain-language title generated from the registry record
Registry title: Circulating Markers That Underlie the Transition From Compensated Hypertrophy to Heart Failure
Key facts
- Where
- Farmington, United StatesSee the site
Where in United States
- University of Connecticut Health CenterFarmington, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- UConn Health
- Trial code
- NCT00762008
- Record updated
- 17 August 2026
- Original description
The purpose of this research is to determine if two proteins in the blood are increased during acute heart failure. These two proteins are produced when the heart becomes dysfunctional and unable to contract normally. They may then be released into the blood and be detected by standard method in the research laboratory. Thus, the purpose of this study is to determine the relation between the change of these two proteins in the blood and the occurrence of acute heart failure. At this time, detection of an increase in these proteins in the blood is not known to be associated with any disease or heart failure.Read full original descriptionShow less
Circulating Markers That Underlie the Transition From Compensated Hypertrophy to Heart Failure
The purpose of this research is to determine if two proteins in the blood are increased during acute heart failure. These two proteins are produced when the heart becomes dysfunctional and unable to contract normally. They may then be released into the blood and be detected by standard method in the research laboratory. Thus, the purpose of this study is to determine the relation between the change of these two proteins in the blood and the occurrence of acute heart failure. At this time, detection of an increase in these proteins in the blood is not known to be associated with any disease or heart failure.
Inclusion: Individuals aged >18yrs; stable or decompensated heart failure, irrespective of LVEF; decompensated heart failure clinical symptoms such as dyspnea, rales, edema, elevated jugular venous pressure, or ascites; Imaging evidence of heart failure (cardiomegaly, poor contractile function or echocardiographic Doppler evidence of diastolic dysfunction or elevated right- or left-sided filling pressures); Healthy individuals with no prior history of heart attack or heart failure will be recruited to use as controls.
Exclusion: Subjects who had undergone cardiac or non-cardiac surgery in the 3 months before enrollment; Subjects who are unable to give informed consent; Pregnant subjects are not excluded.